



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2023-24/117
January 30, 2024

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Please find enclosed herewith copy of press release issued by the Company dated January 30, 2024.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M. No.: F12932



Initiating Commercial Production of Dermatology Product at New Facility in Tarapur, Maharashtra

Mumbai, 30th January 2024

Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS; BSE:524348), a Mumbai based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API), Formulation, Specialty Chemicals and Intermediates announces commencement of production of Dermatology Product at new facility at Tarapur, Maharashtra on 30th January 2024.

The new facility at Tarapur, which is located adjacent to its existing manufacturing units, is equipped with cutting-edge technology and adhering to the highest industry standards, has commenced production of dermatology product from 30th January 2024 with floor area of 40 thousand sq ft. This strategic expansion aligns with company's vision to strengthen its presence in the skincare segment and contribute to the advancement of healthcare.

The dermatology product portfolio encompasses a wide range of formulations designed to address various dermatological conditions, including but not limited to, dermatitis, psoriasis, acne, and eczema. The company's commitment to research and development ensures the continuous evolution of its product offerings to meet the dynamic needs of healthcare professionals and patients.

Total Investment requirement will be ~Rs 150 to Rs 200 crores to complete setting up this facility partially financed through term loan and internal accruals. This facility will have total operational capacity of 24,000 MTPA. Product manufactured will cater to domestic demand at first and with growing opportunities, company shall extend its reach to export markets as well.

Commenting on the same, **Mr. Adhish Patil, CFO & COO, Aarti Drugs Limited said,**

"We are excited to announce the commencement of commercial production of dermatology products at our Tarapur facility. The Tarapur facility, with its state-of-the-art infrastructure and adherence to stringent quality control measures, is poised to be a cornerstone in company's mission to enhance access to quality healthcare solutions. The dermatology segment is a crucial area of focus for us, and with this expansion, we aim to meet the growing demand for innovative solutions in skin care."



About Aarti Drugs Limited

Aarti Drugs Limited was established in the year 1984 and forms part of \$6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its wholly-owned subsidiary-Pinnacle Life Science Private Limited. The Company have total 13 manufacturing facilities out of which 10 manufacturing facilities are in Maharashtra, 2 Manufacturing facilities in Gujarat and 1 Manufacturing facility of Pinnacle is located at Himachal Pradesh. Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

For more information, please visit www.aartidrugs.co.in

For more information, please contact

Company:
Aarti Drugs Limited

Investor Relations (IR)
Strategic Growth Advisors Pvt. Ltd.



CIN: L37060MH1984PLC055433



CIN: U74140MH2010PTC204285

Mr. Rushikesh Deole
investorrelations@aartidrugs.com
+91 22 24048199

Mr. Deven Dhruva / Mr. Harsh Shah
deven.dhruva@sgapl.net / harsh.shah@sgapl.net
+91 98333 73300 / +91 97689 74808

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.